camrelizumab
Jump to navigation
Jump to search
Indications
- neoadjuvant chemotherapy in conjunction with nab-paclitaxel & platinum based chemotherapy (cisplatin, carboplatin or nedaplatin) for patients with resectable stage IIIA or IIIB non-small cell lung carcinoma[1]
Dosage
- 3 cycles of camrelizumab 200 mg)
Mechanism of action
- humanized, selective IgG4-kappa monoclonal antibody against PD-1
Clinical trials
- neoadjuvant camrelizumab added to chemotherapy improved pathologic complete response (median follow-up 14 months)[1]
More general terms
References
- ↑ 1.0 1.1 1.2 Lei J, Zhao J, Gong L et al Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer. The TD-FOREKNOW Randomized Clinical Trial. JAMA Oncol. 2023;9(10):1348-1355 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37535377 PMCID: PMC10401395 Free PMC article https://jamanetwork.com/journals/jamaoncology/fullarticle/2808073